CFTR modulators for the treatment of cystic fibrosis

P and T

Volumn 39, Issue 7, 2014, Pages 500-511

  Pettit, Rebecca S ^a   Fellner, Chris ^b  

^a INDIANA UNIVERSITY HEALTH   (United States)

^b NONE

Author keywords

4PBA; Ataluren; CFTR; CFTR correctors; CFTR modulators; CFTR potentiators; Cystic fibrosis; Cystic fibrosis transmembrane conductance regulator (CFTR); Ivacaftor; Lumacaftor; VRT 532; VX 661

Indexed keywords

AGENTS AFFECTING METABOLISM; ATALUREN; CHLORIDE CHANNEL AFFECTING AGENT; CYCLOSPORIN; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATOR; CYTOCHROME P450 3A; DIGOXIN; FLUCONAZOLE; GENTAMICIN; IVACAFTOR; KETOCONAZOLE; LUMACAFTOR; MIDAZOLAM; MULTIDRUG RESISTANCE PROTEIN; N6022; PLACEBO; SODIUM 4 PHENYLBUTARATE; TACROLIMUS; TOBRAMYCIN; UNCLASSIFIED DRUG; VRT 532; VX 661;

ARTICLE; CYSTIC FIBROSIS; FORCED EXPIRATORY VOLUME; GENE MUTATION; HUMAN; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC);

EID: 84904410000     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (81)

1. O'Sullivan BP, Freedman SD. Cystic fibrosis. Lancet 2009;373:1991-2004.
2. Andersen DH. Cystic fibrosis of the pancreas and its relation to celiac disease: a clinical and pathological study. Am J Dis Child 1938;56:344-399.
3. Lowe CU, May CD, Reed SC. Fibrosis of the pancreas in infants and children: a statistical study of clinical and hereditary features. Am J Dis Child 1949;78:349-374.
4. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989;245:1066-1073.
5. Kerem B, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: genetic analysis. Science 1989;245:1073-1080.
6. Rommens JM, Zengerling-Lentes S, Kerem B, et al. Physical localization of two DNA markers closely linked to the cystic fibrosis locus by pulsed-field gel electrophoresis. Am J Hum Genet 1989;45:932-941.
7. Kerem E, Corey M, Kerem B, et al. The relationship between genotype and phenotype in cystic fibrosis: analysis of the most common mutation (cF508). N Engl J Med 1991;323:1517-1522.
8. Mohon RT, Wagener JS, Abman SH, et al. Relationship of genotype to early pulmonary function in infants with cystic fibrosis identified through neonatal screening. J Pediatr 1993;122:550-555.
9. Welsh MJ, Smith AE. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 1993;73:1251-1254.
10. Rich DP, Anderson MP, Gregory RJ, et al. Expression of cystic fibrosis transmembrane conductance regulator corrects defective chloride channel regulation in cystic fibrosis airway epithelial cells. Nature 1990;347:358-363.
11. Bear CE, Li CH, Kartner N, et al. Purification and functional reconstitution of the cystic fibrosis transmembrane conductance regulator (CFTR). Cell 1992;68:809-818.
12. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med 2005;352:1992-2001.
13. Patient Registry: Annual Data Report 2012. Bethesda, Md.: Cystic Fibrosis Foundation; 2013. Available at: http:// www.cf f.org/UploadedFiles/research/ClinicalResearch/ PatientRegistryReport/2012-CFF-Patient-Registry.pdf. Accessed June 2, 2014.
14. Grasemann H, Ratjen F. Emerging therapies for cystic fibrosis lung disease. Exp Opin Emerg Drugs 2010;15:653-659.
15. Accurso FJ, Rowe SM, Clancy JP, et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 2010;36:1991-2003.
16. American Lung Association. Cystic fibrosis (CF). In: State of Lung Disease in Diverse Communities 2010. Washington, D.C.: American Lung Association; 2010:41-44. Available at: http:// www.lung.org/assets/documents/publications/lung-diseasedata/ solddc_2010.pdf. Accessed June 9, 2014.
17. Milavetz G. Cystic fibrosis. In: DiPiro JT, Talbert RL, Yee GC, et al, eds. Pharmacotherapy: A Pathophysiologic Approach, 7th ed., chapter 32. New York, New York: McGraw Hill Medical; 2008:535-546.
18. World Health Organization. Genes and human disease: monogenic diseases. 2012. Available at: http://www.who.int/genomics/public/ geneticdiseases/en/index2.html#CF. Accessed March 8, 2012.
19. March of Dimes. Cystic fibrosis and pregnancy. Available at: http://www.marchofdimes.com/pregnancy/cystic-fibrosis-andpregnancy. aspx. Accessed June 15, 2014.
20. Cystic Fibrosis Foundation. About cystic fibrosis. Available at: http://www.cff.org/AboutCF. Accessed June 2, 2014.
21. Kliegman RM, Stanton BMD, Geme JS, et al. Nelson's Textbook of Pediatrics, 19th ed. Philadelphia, Pa.: Elsevier Saunders; 2011:1481.
22. Centers for Disease Control and Prevention. ACCE review of CF/ prenatal: clinical validity, version 2002.6. Available at: http://www. cdc.gov/genomics/gtesting/file/print/fbr/cfclival.pdf. Accessed June 15, 2014.
23. Anderson P. Emerging therapies in cystic fibrosis. Ther Adv Resp Dis 2010;4:177-185.
24. Lee TWR, Matthews DA, Blair GE. Novel molecular approaches to cystic fibrosis therapy. Biochem J 2005;387:1-15.
25. Kerem E, Hirawat S, Armoni S, et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 2008;372:719-727.
26. Food and Drug Administration. FDA approves Kalydeco to treat rare form of cystic fibrosis (January 31, 2012). Available at: http:// www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm289633.htm. Accessed March 28, 2013.
27. Kalydeco (ivacaftor) tablets, prescribing information. Cambridge, Massachusetts: Vertex Pharmaceuticals (August 2012). Available at: http://pi.vrtx.com/files/uspi_ivacaftor.pdf. Accessed March 28, 2013.
28. Van Goor F, Hadida S, Grootenhuis PDJ. Pharmacological rescue of mutant CFTR function for the treatment of cystic fibrosis. Top Med Chem 2008;3:91-120.
29. Davies JC, Wainwright CE, Canny GJ, et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with G551D mutation. Am J Respir Crit Care Med 2013;187:1219-1225.
30. Ramsey BW, Davies J, McElvaney G, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011;365:1663-1672.
31. McKone E, Borowitz D, Drevinek P, et al. Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the G551D-CFTR mutation: response through 144 weeks of treatment (96 weeks of PERSIST). Poster presented as part of the North American Cystic Fibrosis Conference, Salt Lake City, Utah, October 1-19, 2013. Abstract published in Pediatr Pulmonol 2013;(suppl 36):287.
32. Davies J, Sheridan H, Bell N, et al. Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomized controlled trial. Lancet Respir Med 2013;1:630-638.
33. Elborn JS, Rodriguez S, Lubarsky B, et al. Effect of ivacaftor in patients with cystic fibrosis and the G551D-CFTR mutation who have baseline FEV1 > 90% of predicted. Poster presented as part of the North American Cystic Fibrosis Conference, Salt Lake City, Utah, October 1-19, 2013. Abstract published in Pediatr Pulmonol 2013(suppl 36):298.
34. Barry PJ, Plant BJ, Nair A, et al. Effects of ivacaftor in cystic fibrosis patients carrying the G551D mutation with severe lung disease. Chest 2014 [Epub ahead of print February 13]:1-48.
35. Flume PA, Liou TG, Borowitz DS, et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest 2012;142:718-724.
36. Vertex Pharmaceuticals. Vertex announces results of phase 3 study of ivacaftor in people with CF who have the R117H mutation. (December 19, 2013). Available at: http://investors.vrtx.com/ releasedetail.cfm?ReleaseID=814799. Accessed March 2, 2014.
37. De Boeck K, Gilmartin G, Chen X, et al. Ivacaftor, a CFTR potentiator, in cystic fibrosis patients who have a non-G551D-CFTR gating mutation: phase 3, part 1 results. Poster presented as part of the North American Cystic Fibrosis Conference, Salt Lake City, Utah, October 17-19, 2013. Abstract published in Pediatr Pulmonol 2013(suppl 36):292.
38. Vertex Pharmaceuticals. U.S. Food and Drug Administration approves Kalydeco (ivacaftor) for use in eight additional mutations that cause cystic fibrosis. (February 21, 2014). Available at: http://investors.vrtx.com/releasedetail.cfm?ReleaseID=827435. Accessed March 2, 2014.
39. Kalydeco [Product Monograph]. Laval, Quebec: Vertex Pharmaceuticals (Canada) Inc.; 2012.
40. National Institutes of Health. An ocular safety study of ivacaftortreated pediatric patients 11 years of age or younger with cystic fibrosis (May 22, 2013). Available at: http://clinicaltrials.gov/ct2/ show/NCT01863238. Accessed October 29, 2013.
41. Barry PJ, Jones AM, Webb AK, et al. Sweat chloride is not a useful marker of clinical response to ivacaftor. Thorax 2013;0:1-2.
42. Red Book Online. Ann Arbor, Michigan; Truven Health Analytics. Accessed May 28, 2014.
43. Gever J. FDA approves cystic fibrosis drug. www.medpagetoday. com/Pulmonology/CysticFibrosis/30936. Accessed March 6, 2012.
44. Rowe SM, Heltshe SL, Gonska T, et al. Clinical mechanism of the CFTR potentiator ivacaftor in G551D-mediated cystic fibrosis. Am J Respir Crit Care Med 2014; [Epub ahead of print June 13]:1-44.
45. Sly PD, Brennan S, Gangell C, et al. Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening. Am J Respir Crit Care Med 2009;180:146-152.
46. National Institutes of Health. Study of ivacaftor in cystic fibrosis subjects 2 through 5 years of age with a CFTR gating mutation (October 8, 2012). Available at: http://clinicaltrials.gov/ct2/show/ NCT01705145. Accessed October 29, 2013.
47. Van Goor F, Hadida S, Grootenhuis PD, et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci USA 2011;108:18843-18848.
48. Clancy JP, Rowe SM, Accurso FJ, et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 2012;67:12-18.
49. Boyle M, Bell S, Konstan M, et al. Lumacaftor, an investigational CFTR corrector, in combination with ivacaftor, a CFTR potentiator, in CF patients with the F508del-CFTR mutation. Presentation at European Cystic Fibrosis Conference, Lisbon, Portugal, June 12-15, 2013.
50. Boyle MP, Bell S, Konstan MW, et al. VX-809, an investigational CFTR corrector, in combination with VX-770, an investigational CFTR potentiator, in subjects with CF and homozygous for the F508DEL-CFTR mutation. Abstract published in Pediatr Pulmonol 2011;46(suppl 34):287.
51. Boyle MP, Bell S, Konstan MW, et al. The investigational CFTR corrector, VX-809 (lumacaftor) co-administered with the oral potentiator ivacaftor improved CFTR and lung function in F508Del homozygous patients: phase II study results. Poster presented as part of the North American Cystic Fibrosis Conference, Orlando, Florida, October 11-13, 2012. Abstract published in Pediatr Pulmonol 2012;(suppl 35):315.
52. Vertex Pharmaceuticals. Vertex announces initiation of pivotal phase 3 program of VX-809 in combination with ivacaftor for the treatment of people with cystic fibrosis who have two copies of the F508del mutation (February 26, 2013). Available at: http://investors.vrtx.com/releasedetail.cfm?ReleaseID=743425. Accessed April 8, 2013.
53. National Institutes of Health. A study of lumacaftor in combination with ivacaftor in cystic fibrosis subjects aged 12 years and older who are homozygous for the F508del-CFTR mutation (TRAFFIC). Available at: http://clinicaltrials.gov/show/NCT01807923. Accessed June 9, 2014.
54. National Institutes of Health. A study of lumacaftor in combination with ivacaftor in cystic fibrosis subjects aged 12 years and older who are homozygous for the F508del-CFTR mutation (TRANSPORT). Available at: http://clinicaltrials.gov/show/NCT01807923. Accessed June 9, 2014.
55. Vertex Pharmaceuticals. Vertex and Cystic Fibrosis Foundation Therapeutics to collaborate on discovery and development of new medicines to treat the underlying cause of cystic fibrosis (April 7, 2011). Available at: http://investors.vrtx.com/releasedetail. cfm?releaseid=563453. Accessed March 29, 2013.
56. National Institutes of Health. Study of VX-661 alone and in combination with VX-770 in subjects homozygous to the F508del-CFTR mutation (March 9, 2012). Available at: http://clinicaltrials.gov/ ct2/show/NCT01531673. Accessed March 29, 2013.
57. Donaldson S, Pilewski J, Griese M, et al. VX-661, an investigational CFTR corrector, in combination with ivacaftor, a CFTR potentiator, in patients with CF homozygous for the F508del-CFTR mutation, interim analysis. Presentation at European Cystic Fibrosis Conference, Lisbon, Portugal, June 12-15, 2013.
58. Du M, Liu X, Welch EM, et al. PTC124 is an orally bioavailable compound that promotes suppression of the human CFTRG542X nonsense allele in a CF mouse model. Proc Natl Acad Sci USA 2008;105:2064-2069.
59. Hamed SA. Drug evaluation: PTC-124: a potential treatment of cystic fibrosis and Duchenne muscular dystrophy. IDrugs 2006;9:783-789.
60. Ratjen FA. Cystic fibrosis: Pathogenesis and future treatment strategies. Respir Care 2009;54:595-602.
61. Welch E, Barton E, Zhuo J, et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 2007;447:87-91.
62. Hirawat S, Welch EM, Elfring GL, et al. Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single-and multiple-dose administration to healthy male and female adult volunteers. J Clin Pharmacol 2007;47:430-444.
63. PTC Therapeutics. Ataluren for genetic disorders (2012). Available at: http://www.ptcbio.com/ataluren. Accessed March 29, 2013.
64. Sermet-Gaudelus I, De Boeck K, Casimir GJ, et al. Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. Am J Respir Crit Care Med 2010;182:1262-1272.
65. Wilschanski M, Miller LL, Shoseyov D, et al. Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis. Eur Respir J 2011;38:59-69. Erratum: Eur Respir J 2011;38:996.
66. Kerem E, Konstan MW, De Boeck K, et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomized, doubleblind, placebo-controlled phase 3 trial. Lancet Respir Med 2014; [Epub ahead of print, May 15].
67. National Institutes of Health. Extension study of ataluren (PTC124) in cystic fibrosis (August 16, 2011). Available at: http://clinicaltrials. gov/ct2/show/NCT01140451. Accessed March 30, 2013.
68. Exclusive Chemistry Ltd. CFTR modulators for treatment of cystic fibrosis-35 compounds. Available at: http://www.exchemistry. com/chem-catalog/cftr-compounds/. Accessed April 5, 2013.
69. Rubenstein RC, Egan ME, Zeitlin PL. In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing ΔF508-CFTR. J Clin Invest 1997;100:2457-2465.
70. Rubenstein RC, Zeitlin PL. A pilot clinical trial of oral sodium 4-phenylbutyrate (buphenyl) in ΔF508-homozygous cystic fibrosis patients: Partial restoration of nasal epithelial CFTR function. Am J Respir Crit Care Med 1998;157:484-490.
71. Zeitlin PL, Diener-West M, Rubenstein RC, et al. Evidence of CFTR function in cystic fibrosis after systemic administration of 4-phenylbutyrate. Mol Ther 2002;6:119-126.
72. Lim M, McKenzie K, Floyd AD, et al. Modulation of ΔF508 cystic fibrosis transmembrane regulator trafficking and function with 4-phenylbutyrate and flavonoids. Am J Respir Cell Mol Biol 2004;31:351-357.
73. Rubenstein RC, Propert KJ, Reenstra WW, Skotleski ML. A pilot trial of the combination of phenylbutyrate and genistein. Abstract published in Pediatr Pulmonol 2006;41(suppl 29):248.
74. Van Goor F, Straley KS, Cao D, et al. Rescue of deltaF508 CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Lung Cell Mol Physiol 2006;290:L1117-L1130.
75. Wang Y, Bartlett MC, Loo TW, Clarke DM. Specific rescue of cystic fibrosis transmembrane conductance regulator processing mutants using pharmacological chaperones. Mol Pharmacol 2006;70:297-302.
76. Wang Y, Loo TW, Bartlett MC, Clarke DM. Correctors promote maturation of cystic fibrosis transmembrane conductance regulator (CFTR)-processing mutants by binding to the protein. J Biol Chem 2007;282:33247-33251.
77. Wellhauser L, Chiaw PK, Pasyk S, et al. A small-molecule modulator interacts directly with phe508-CFTR to modify its ATPase activity and conformational stability. Mol Pharmacol 2009;75:1430-1438.
78. Pasyk S, Li C, Ramjeesingh M, Bear CE. Direct interaction of a small-molecule modulator with G551D-CFTR, a cystic fibrosis-causing mutation associated with severe disease. Biochem J 2009;418:185-190.
79. N6022. Available at: http://www.cff.org/treatments/Pipeline/. Accessed March 2, 2014.
80. NS30 Pharma. N30 Pharmaceuticals announces first patient treated in clinical trial of N6022 in cystic fibrosis. Available at: http://www.n30pharma.com/docs/news/2013-03-12-6022-CFFirst-Patient.pdf. Accessed June 9, 2014.
81. National Institutes of Health. Safety and pharmacokinetic study of N6022 in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation (SNO-2) (December 6, 2012). Available at: http:// clinicaltrials.gov/show/NCT01746784. Accessed March 2, 2014.